Akero Therapeutics, Inc.
AKRONASDAQHealthcare
$54.65
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$58.4
52W Low$21.34
Akero Therapeutics, Inc.（AKRO）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AKRO · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.25B | $0.14B | $0.09B | $0.08B | $0.06B |
| G&A Expenses | $0.04B | $0.03B | $0.03B | $0.02B | $0.02B |
| Total Operating Expenses | $0.29B | $0.17B | $0.12B | $0.10B | $0.08B |
| Operating Income | ($0.29B) | ($0.17B) | ($0.12B) | ($0.10B) | ($0.08B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.04B | $0.02B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.25B) | ($0.15B) | ($0.11B) | ($0.10B) | ($0.08B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.25B) | ($0.15B) | ($0.11B) | ($0.10B) | ($0.08B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.75 | $-2.89 | $-2.87 | $-2.89 | $-2.52 |
| Wtd Avg Shares | 0.07B | 0.05B | 0.04B | 0.03B | 0.03B |
| EBITDA | ($0.25B) | ($0.15B) | ($0.11B) | ($0.10B) | ($0.08B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Akero Therapeutics, Inc.
关于Akero Therapeutics, Inc.（AKRO）损益表
Akero Therapeutics, Inc.（AKRO）损益表数据来源于SEC Form 10-K及10-Q申报文件。2024财年，AKRO实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.25B)（净利率—）。
常见问题
AKRO · 4 问Akero Therapeutics, Inc.（AKRO）2024财年营收为$0.00B，同比down—%。
AKRO revenueAKRO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08